TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 26242177
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of rocuronium 0.6 mg/kg per hour
Study: 26242177
Drug: Continuous infusion
Normalized name: insulin pump cartridge,continuous infusion,BT and controller SUBCUT EACH
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of NaCl 0.9 % 0.06 ml/kg per hour
Study: 23954097
Drug: Calcium carbonate
Normalized name: Calcium Carbonate
DrugBank: Calcium carbonate (DB06724)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Calcium carbonate (1,000 mg as elemental calcium) with vitamin D‐3 (400 IU) daily
Study: 20948291
Drug: Muromonab CD3
Normalized name: Muromonab-Cd3
DrugBank: Muromonab (DB00075)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Muromonab CD3 (monoclonal antibody targeting CD3)
Study: 20948291
Drug: Novel monoclonal
Normalized name: factor VIII
DrugBank: Beroctocog alfa (DB14473)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Novel monoclonal antibodies targeting co‐stimulatory signals, cell surface receptors, and novel protein constructs
Study: 12727577
Drug: Aggressive lipid-lowering
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Aggressive lipid-lowering strategy involving up to 80 mg/d of atorvastatin with a target LDL cholesterol level <77 mg/dL
Study: 12727577
Drug: Usual therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usual therapy of lipids with LDL cholesterol target level <116 mg/dL
Study: 8222384
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg SIN-1 administered via intracoronary route
Study: 8222384
Drug: 0.4 mg
Normalized name: biotin 0.4 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.4 mg SIN-1 administered via intravenous route
Study: 3899346
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with previous treatment
Study: 3899346
Drug: Patients with
Normalized name: Primatene with ephedrine Pill
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients with no previous treatment
Study: 24851997
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusion to maintain platelet counts at or above 50 × 10(9)/l
Study: 24851997
Drug: Prophylactic platelet
Normalized name: platelet glycoprotein VI
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prophylactic platelet transfusion to maintain platelet counts at or above 25 × 10(9)/l
Study: 9390111
Drug: SDZ HTF
Normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ HTF 919 25 mg
Study: 9390111
Drug: SDZ HTF
Normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ HTF 919 100 mg
Study: 9390111
Drug: SDZ HTF
Normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ HTF 919 1 mg
Study: 9390111
Drug: SDZ HTF
Normalized name: SDZ MSL 109
DrugBank: Sevirumab (DB17771)
Approvals — FDA: no, EMA: no, PMDA: no
Description: SDZ HTF 919 5 mg
Study: 7962372
Drug: Classical vaporization
Approvals — FDA: no, EMA: no, PMDA: no
Description: Classical vaporization of the ovarian capsule (22 women)
Study: 7962372
Drug: Simple perforation
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Simple perforation of the ovarian capsule with subcapsular destruction of the ovarian stroma (22 women)
Study: 7962372
Drug: Overall conception
Approvals — FDA: no, EMA: no, PMDA: no
Description: Overall conception rate after laparoscopic argon laser treatment
Study: 7962372
Drug: Clomiphene citrate
Normalized name: Clomiphene Citrate
DrugBank: Clomifene (DB00882)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clomiphene citrate therapy post-operatively
Study: 28642082
Drug: 50,000IU vitamin
Approvals — FDA: no, EMA: no, PMDA: no
Description: 50,000IU vitamin D supplements
Study: 17033039
Drug: Docetaxel 60
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 60 mg/m2
Study: 14585088
Drug: Training program
Approvals — FDA: no, EMA: no, PMDA: no
Description: Training program (8 weeks of supervised endurance exercise, 75% VO(2peak), 45 min twice a week, with intermittent exercise once a week)
Study: 10922194
Drug: Oral acyclovir,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral acyclovir, 800 mg/d
Study: 30803168
Drug: Intestinal preparation
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intestinal preparation with polyethylene glycol
Study: 30803168
Drug: Non intestinal
Normalized name: pork intestine preparation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Non intestinal preparation
Study: 21939591
Drug: Cognitive behaviour
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cognitive behaviour therapy for psychosis (CBT-P)
Study: 19584345
Drug: 2-dose PCV-7
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-dose PCV-7 schedule (2 and 4 months)
Study: 19584345
Drug: 2 +
Normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 + 1-dose PCV-7 schedule (2, 4, and 11 months)
Study: 19584345
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no dosage)
Study: 19584345
Drug: 2 +
Normalized name: dHER2 + AS15 ASCI
DrugBank: SB719125 (DB16753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 + 1-dose PCV-7 schedule
Study: 19584345
Drug: 2-dose PCV-7
Normalized name: PCV
DrugBank: Penciclovir (DB00299)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 2-dose PCV-7 schedule
Study: 18240275
Drug: 300 mg
Normalized name: rutin 300 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 300 mg antofloxacin hydrochloride
Study: 18240275
Drug: 400 mg
Normalized name: mesna 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 400 mg antofloxacin hydrochloride
Study: 18240275
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg antofloxacin hydrochloride
Study: 14562857
Drug: Triple drug
Approvals — FDA: no, EMA: no, PMDA: no
Description: Triple drug regimens containing Nevirapine
Study: 8899318
Drug: Ukrain treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Ukrain treatment in preoperative phase
Study: 8899318
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no Ukrain treatment)
Study: 1844999
Drug: Polylactate (PL:
Approvals — FDA: no, EMA: no, PMDA: no
Description: Polylactate (PL: 80% polylactate, 20% sodium lactate, in 7% solution with water)
Study: 1844999
Drug: Glucose polymer
Normalized name: glucose polymers
Approvals — FDA: no, EMA: no, PMDA: no
Description: Glucose polymer (GP: multidextrin in 7% solution with water)
Study: 6097377
Drug: Enalapril (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril (10 mg p.o.) in acute studies
Study: 6097377
Drug: Enalapril titrated
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enalapril titrated from 5 mg to 20 mg twice a day in chronic studies
Study: 27127325
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + AZM tablets
Study: 27127325
Drug: AZM patch
Normalized name: Azmiro
DrugBank: Testosterone cypionate (DB13943)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZM patch monotherapy
Study: 27127325
Drug: AZM tablet
Normalized name: Azmiro
DrugBank: Acetazolamide (DB00819)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: AZM tablet as monotherapy
Study: 27127325
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + AZM patch
Study: 27127325
Drug: SRP +
Normalized name: loratadine
DrugBank: Loratadine (DB00455)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: SRP + AZM tablet
Study: 19161955
Drug: Sunflower Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sunflower Therapy
Study: 17313701
Drug: Intravenous infusion
Normalized name: intravenous infusion pump accessory
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous infusion of pancreatic polypeptide (PP) at 5 pmol/kg per min
Study: 17313701
Drug: PP infusion
Normalized name: Duo Fusion
DrugBank: Magnesium hydroxide (DB09104)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: PP infusion
Study: 15356657
Drug: Low-dose etoposide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose etoposide (50 mg/m² per day) administered orally as a single agent for 7 days
Study: 15356657
Drug: Low-dose etoposide
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose etoposide (50 mg/m² per day) administered orally
Study: 11254520
Drug: Intervention group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention group (n = 49) with a respiratory therapist‐driven weaning protocol including daily screens and spontaneous breathing trials (SBT) for 2 hours.
Study: 1153148
Drug: DMPA (Depo-Provera,
Approvals — FDA: no, EMA: no, PMDA: no
Description: DMPA (Depo-Provera, Upjohn) 150 mg IM monthly
Study: 1153148
Drug: Sterile saline
Normalized name: Aqua Care Sterile Saline
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sterile saline 1.5 ml IM monthly (Control)
Study: 31837640
Drug: Zinc (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (30 mg/d)
Study: 31837640
Drug: Zinc (30
Approvals — FDA: no, EMA: no, PMDA: no
Description: Zinc (30 mg/d) + Vitamin D (2000 IU/d)
Study: 28494777
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy plus oseltamivir
Study: 28494777
Drug: Antimicrobial therapy
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antimicrobial therapy alone (control group)
Study: 21226960
Drug: Self-help coping
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-help coping advice emails (twice weekly for six weeks)
Study: 21226960
Drug: General information
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: General information about depression emails (twice weekly for six weeks)
Study: 18157642
Drug: Transurethral collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral collagen injection midurethrally
Study: 18157642
Drug: Transurethral collagen
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transurethral collagen injection at the bladder neck
Study: 8785393
Drug: Long-term RHSD
Normalized name: benzethonium
DrugBank: Benzethonium (DB11125)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Long-term RHSD therapy
Study: 6666222
Drug: 60 mg
Normalized name: opium 60 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 60 mg ISDN sr
Study: 30659468
Drug: New standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: New standard operating procedure (SOP) using a combination of esketamine and propofol
Study: 28110894
Drug: High-risk patients
Normalized name: high-density polyethylene
Approvals — FDA: no, EMA: no, PMDA: no
Description: High-risk patients (hs-CRP ≥3.84mg/L and Lp-PLA2 >239μg/L)
Study: 23283254
Drug: Topical ice
Normalized name: Camphor Ice Topical Product
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical ice pack
Study: 11021442
Drug: Porous‐coated Miller‐Galante
Approvals — FDA: no, EMA: no, PMDA: no
Description: Porous‐coated Miller‐Galante II (MG II) total knee arthroplasty
Study: 9070551
Drug: Trandolapril 1
Normalized name: trandolapril 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 1 mg/day for 1 month and 2 mg/day for the following 2 months (n = 49)
Study: 9070551
Drug: Trandolapril 1
Normalized name: trandolapril 1 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trandolapril 1 mg/day for 1 month and 2 mg/day for the following 2 months plus Verapamil 240 mg/day for 1 month and 360 mg/day for 2 months (n = 51)
Study: 12959317
Drug: Oxcarbazepine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (600 mg) in patients on phenobarbitone
Study: 12959317
Drug: Oxcarbazepine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (600 mg) in patients on sodium valproate
Study: 12959317
Drug: Oxcarbazepine (600
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxcarbazepine (600 mg) in healthy control subjects
Study: 31758920
Drug: Drospirenone (DRSP)
Normalized name: Drospirenone
DrugBank: Drospirenone (DB01395)
Approvals — FDA: yes, EMA: yes, PMDA: no
Description: Drospirenone (DRSP) 3 mg and Ethinyl Estradiol (EE) 0.02 mg
Study: 24906459
Drug: Exercise dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise dose for general health (8 kcal/kg body weight per week, about 900 kcal/wk)
Study: 24906459
Drug: Exercise dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Exercise dose for weight loss (20 kcal/kg body weight per week, about 2,250 kcal/wk)
Study: 23770788
Drug: Allopurinol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Allopurinol (10 mg/kg body weight, 3 times before operation)
Study: 21364503
Drug: Lidocaine 40
Normalized name: lidocaine 400 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaine 40 mg and Flurbiprofen axetil 50 mg (combination)
Study: 18485028
Drug: Docetaxel 70
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 70 mg/m² on day 1 (arm A)
Study: 18485028
Drug: Docetaxel 70
Normalized name: Docetaxel
DrugBank: Docetaxel (DB01248)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Docetaxel 70 mg/m² on day 2 plus oral estramustine phosphate (EP) 840 mg total daily dose on days 1-5 (arm B)
Study: 16455821
Drug: Intervention schools
Normalized name: cetylpyridinium chloride Topical Spray [Rocco's Old School]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intervention schools received staff asthma-training session, advice on asthma policy, an emergency beta2-agonist inhaler with spacer, and whole-class asthma workshops.
Study: 14553956
Drug: Lisinopril (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lisinopril (0.07 mg/kg once daily)
Study: 11061364
Drug: Cilazapril 20
Normalized name: cilazapril
DrugBank: Cilazapril (DB01340)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cilazapril 20 mg/day
Study: 8931406
Drug: Prior antibiotics
Normalized name: Priorix
DrugBank: Rubella virus vaccine (DB10317)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Prior antibiotics
Study: 2439798
Drug: bisoprolol (0.07
Approvals — FDA: no, EMA: no, PMDA: no
Description: bisoprolol (0.07 mg/kg i.v.)
Study: 2439798
Drug: metoprolol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: metoprolol (0.2 mg/kg i.v.)
Study: 2439798
Drug: acebutolol (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: acebutolol (0.8 mg/kg i.v.)
Study: 2439798
Drug: penbutolol (0.04
Approvals — FDA: no, EMA: no, PMDA: no
Description: penbutolol (0.04 mg/kg i.v.)
Study: 2439798
Drug: propranolol (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: propranolol (0.2 mg/kg i.v.)
Study: 20597141
Drug: Donepezil (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (10 mg/day over 24 weeks)
Study: 16002019
Drug: Single-dose oral
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose oral ciprofloxacin (500 mg)
Study: 16002019
Drug: Single-dose intravenous
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single-dose intravenous cefazolin (1g)
Study: 7805081
Drug: Less intense
Approvals — FDA: no, EMA: no, PMDA: no
Description: Less intense anticoagulant regimens with or without concomitant antiplatelet therapy
Study: 7805081
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants for tissue valves
Study: 7805081
Drug: Oral anticoagulants
Normalized name: CPDA-1 Anticoagulant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral anticoagulants for mechanical valves
Study: 12177586
Drug: Agomelatine 25
Normalized name: Agomelatine 25 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine 25 mg once a day
Study: 12177586
Drug: Agomelatine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Agomelatine (1 mg, 5 mg, 25 mg)
Study: 7610473
Drug: Daily administration
Normalized name: Prevpac 30mg-500mg-500mg Daily Administration Pack
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daily administration of 50 gr protein for 2000 kcal
Study: 2231217
Drug: Cisapride (7.5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Cisapride (7.5 to 10 mg) three times daily for 6 months
Study: 2231217
Drug: Placebo three
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo three times daily for 6 months
Study: 302373
Drug: Methylprednisolone (MP)
Normalized name: Methylprednisolone
DrugBank: Methylprednisolone (DB00959)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Methylprednisolone (MP) 2 Gm administered 1/2 hour prior to cardiopulmonary bypass (CPB)
Study: 302373
Drug: Control group
Normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control group (no MP treatment)
Study: 31090968
Drug: Weekly alerts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Weekly alerts to providers
Study: 31090968
Drug: Both interventions
Normalized name: Bothrops atrox venom
Approvals — FDA: no, EMA: no, PMDA: no
Description: Both interventions (financial incentives and weekly alerts)
Study: 15063428
Drug: Atorvastatin (n
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin (n = 28)
Study: 8179230
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 200 micrograms, twice daily
Study: 8179230
Drug: Fluticasone propionate,
Normalized name: fluticasone propionate, micronized
Approvals — FDA: no, EMA: no, PMDA: no
Description: Fluticasone propionate, 200 micrograms, once daily
Study: 20503397
Drug: Supplement containing
Normalized name: fish oil (containing omega-3 acids) Injection [Omegaven]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Supplement containing isoflavones and curcumin
Study: 16226371
Drug: Methylphenidate 0.3mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Methylphenidate 0.3mg/kg per dose PO BID from the second day of admission until discharge
Study: 10389911
Drug: HER-2/neu peptide-based
Approvals — FDA: no, EMA: no, PMDA: no
Description: HER-2/neu peptide-based vaccine
Study: 8916623
Drug: Treatment for
Normalized name: Hair Regrowth Treatment For Men
DrugBank: Minoxidil (DB00350)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Treatment for anxiety disorders
Study: 1876247
Drug: Intrathecally administered
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecally administered morphine 0.125 mg
Study: 1876247
Drug: Intrathecally administered
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecally administered morphine 0.25 mg
Study: 1876247
Drug: Intrathecally administered
Normalized name: beractant
DrugBank: Beractant (DB06761)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intrathecally administered morphine 0.5 mg
Study: 1876247
Drug: Systemic narcotic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systemic narcotic administration
Study: 6819276
Drug: 14 MeV
Approvals — FDA: no, EMA: no, PMDA: no
Description: 14 MeV d + T fast neutrons; Dosage: 18 to more than 22 Gy; Treatment method: two parallel opposed ports
Study: 6819276
Drug: High dose
Normalized name: INFLUENZA VACCINE HIGH DOSE 0.5ML SYR
Approvals — FDA: no, EMA: no, PMDA: no
Description: High dose neutrons; Treatment method: randomized in a three arm trial
Study: 31594635
Drug: Relugolix (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Relugolix (40 mg once daily for 12 weeks)
Study: 24122836
Drug: Amoxicillin 750
Normalized name: amoxicillin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 750 mg bid
Study: 24122836
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg tid
Study: 24122836
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg qid
Study: 24122836
Drug: Amoxicillin 750
Normalized name: amoxicillin 750 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 750 mg bid with metronidazole 250 mg bid
Study: 24122836
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg tid with metronidazole 250 mg bid
Study: 24122836
Drug: Amoxicillin 500
Normalized name: amoxicillin 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amoxicillin 500 mg qid with metronidazole 250 mg bid
Study: 11843929
Drug: Topical oxymetazoline
Normalized name: oxymetazoline Topical Cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Topical oxymetazoline (decongestion)
Study: 9542322
Drug: IFN dose
Normalized name: IFNγ
DrugBank: Interferon Gamma (DB15753)
Approvals — FDA: no, EMA: no, PMDA: no
Description: IFN dose > or = 30 MU/month
Study: 3291557
Drug: Propafenone, 150
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propafenone, 150 mg four times daily
Study: 3291557
Drug: Disopyramide, 100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Disopyramide, 100 mg four times daily
Study: 330483
Drug: amoxycillin 250
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxycillin 250 mg and pivmecillinam 200 mg
Study: 330483
Drug: amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxycillin 500 mg
Study: 330483
Drug: amoxycillin 500
Normalized name: Amoxycillin
DrugBank: Amoxicillin (DB01060)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: amoxycillin 500 mg and pivmecillinam 400 mg
Study: 31547438
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (sodium restriction + hydrochlorothiazide)
Study: 28145162
Drug: Corticosteroids plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Corticosteroids plus standard treatment (TMP/SMX)
Study: 28145162
Drug: Standard treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard treatment plus placebo
Study: 24266960
Drug: Intensive lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive lipid lowering (target LDL-c < 1.4 mmol/l)
Study: 24266960
Drug: Guideline lipid
Normalized name: guggul lipids
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guideline lipid lowering (target LDL-c < 3 mmol/l)
Study: 24266960
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure lowering therapy for hemorrhagic stroke
Study: 24266960
Drug: Intensive blood
Normalized name: dragon's blood extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intensive blood pressure lowering therapy for ischemic stroke